Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMNAU1V)

Drug Name

ABT-436 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Anxiety disorder	6B00-6B0Z	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Vasopressin V1b receptor (V1BR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Desmopressin	DMS3GVE	Diabetic complication	5A2Y	Approved	[3]
Mozavaptan	DMZ905C	Hyponatraemia	5C72	Approved	[4]
Oxytocin	DMDL27I	Autism spectrum disorder	6A02	Approved	[5]
ATOSIBAN	DMB7WYM	N. A.	N. A.	Phase 4	[6]
SSR149415	DMCMD93	Anxiety disorder	6B00-6B0Z	Phase 2	[7]
ARGENINE VASOPRESSIN	DM8KN0Q	Discovery agent	N.A.	Investigative	[8]
D[Arg4,Orn8]VP	DM8D4QT	Discovery agent	N.A.	Investigative	[8]
D[Leu4,Lys8]VP	DMDBU7Q	Discovery agent	N.A.	Investigative	[8]
D[Arg4,Lys8]VP	DM69OVM	Discovery agent	N.A.	Investigative	[8]
D[Cha4,Lys8]VP	DM0GO7U	Discovery agent	N.A.	Investigative	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT01741142) Efficacy and Safety Study of ABT-436 in Major Depressive Disorder. U.S. National Institutes of Health.
2	The vasopressin Avprlb receptor: Molecular and pharmacological studies. Stress. 2011 January; 14(1): 98-115.
3	Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4. J Med Chem. 2004 Apr 22;47(9):2375-88.
4	New analgesic drugs derived from phencyclidine. J Med Chem. 1981 May;24(5):496-9.
5	The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways. Endocrinology. 1997 Oct;138(10):4109-22.
6	The discovery of GSK221149A: a potent and selective oxytocin antagonist. Bioorg Med Chem Lett. 2008 Jan 1;18(1):90-4.
7	Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
8	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.